Sugi Predict

Sugi Predict / Compounds / SCHEMBL22964741

SCHEMBL22964741

SCHEMBL22964741

Cc1nc(Nc2ncc(C(=O)Nc3c(Br)cccc3Br)s2)cc(N2CCN(CCO)CC2)n1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 12/20 0.84
▸ SIK2 Q9H0K1 12/20 0.84
▸ SIK3 Q9Y2K2 12/20 0.84
▸ SIK1 P57059 10/20 0.84
▸ SRC P12931 5/20 0.79
▸ PKMYT1 Q99640 3/20 0.79
▸ EPHB6 O15197 2/20 0.79
▸ EGFR P00533 2/20 0.79
▸ LCK P06239 2/20 0.79
▸ FYN P06241 2/20 0.79
▸ CSF1R P07333 2/20 0.79
▸ YES1 P07947 2/20 0.79
▸ LYN P07948 2/20 0.79
▸ RET P07949 2/20 0.79
▸ HCK P08631 2/20 0.79
▸ KIT P10721 2/20 0.79
▸ BCR P11274 2/20 0.79
▸ BRAF P15056 2/20 0.79
▸ EPHA1 P21709 2/20 0.79
▸ EPHA2 P29317 2/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30633438 0.95 ABL1 (0.86) ABL1SIK2SIK3SIK1SRC
SCHEMBL20536999 0.95 ABL1 (0.78) ABL1SIK2SIK3SIK1SRC
SCHEMBL21875017 0.95 ABL1 (0.86) ABL1SIK2SIK3SIK1SRC
SCHEMBL31634940 0.95 ABL1 (0.78) ABL1SIK2SIK3SIK1SRC
SCHEMBL13378598 0.92 ABL1 (0.89) ABL1SIK2SIK3SIK1SRC
SCHEMBL31634945 0.92 ABL1 (0.89) ABL1SIK2SIK3SIK1SRC
SCHEMBL21875024 0.91 SIK2 (1.00) ABL1SIK2SIK3SIK1SRC
SCHEMBL30152042 0.91 SIK2 (1.00) ABL1SIK2SIK3SIK1SRC
SCHEMBL1704876 0.90 ABL1 (0.92) ABL1SIK2SIK3SIK1SRC
SCHEMBL20537134 0.90 ABL1 (0.79) ABL1SIK2SIK3SIK1SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250340886-A1 INTRACELLULAR KINASE ASSOCIATED WITH RESISTANCE AGAINST ANTI-TUMOUR IMMUNE RESPONSES, AND USES THEREOF IOMX THERAPEUTICS AG (DE) 2025-11-06 — — US disclosed
US-12338440-B2 Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereof IOMX THERAPEUTICS AG (DE) 2025-06-24 — — US disclosed
US-20210040486-A1 INTRACELLULAR KINASE ASSOCIATED WITH RESISTANCE AGAINST ANTI-TUMOUR IMMUNE RESPONSES, AND USES THEREOF IOMX THERAPEUTICS AG (DE) 2021-02-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210040486-A1 INTRACELLULAR KINASE ASSOCIATED WITH RESISTANCE AGAINST ANTI-TUMOUR IMMUNE RESPONSES, AND USES THEREOF SIK3, SIK1, SIK2 ABL1 1088/4885SIK2 3/4885SIK3 1/4885
US-20250340886-A1 INTRACELLULAR KINASE ASSOCIATED WITH RESISTANCE AGAINST ANTI-TUMOUR IMMUNE RESPONSES, AND USES THEREOF SIK3, SIK1, SIK2 ABL1 1088/4885SIK2 3/4885SIK3 1/4885
US-12338440-B2 Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereof SIK3, SIK1, SIK2 ABL1 1088/4885SIK2 3/4885SIK3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.